Association of Lower Serum Bilirubin With Loss of Residual Kidney Function in Peritoneal Dialysis Patients.
Bilirubin
End-stage renal disease
Peritoneal dialysis
Residual kidney function
Journal
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
ISSN: 1744-9987
Titre abrégé: Ther Apher Dial
Pays: Australia
ID NLM: 101181252
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
06
02
2019
revised:
08
05
2019
accepted:
12
06
2019
pubmed:
18
6
2019
medline:
15
12
2020
entrez:
18
6
2019
Statut:
ppublish
Résumé
Bilirubin is recognized as an endogenous antioxidant, and low serum bilirubin is reported to be associated with the progression of kidney disease. However, it is unclear whether serum bilirubin levels are associated with the loss of residual kidney function (RKF) in peritoneal dialysis (PD) patients. This study investigated the relationship between serum total bilirubin and loss of RKF. We prospectively followed 94 PD patients who started PD in our hospital between June 2006 and May 2016. Ten patients who had chronic liver disease or cirrhosis were excluded. Patients were divided into three groups based on serum total bilirubin concentration tertiles: tertile 1 (T1) < 0.3, T2 = 0.3, and T3 ≥ 0.4 mg/dL. We estimated the relationship between serum bilirubin and loss of RKF, defined as daily urine volume (<100 mL) within 3 years after starting PD, using a Cox proportional hazards model. During the 3-year observation period, 22 patients lost RKF. The incidence rate of loss of RKF increased linearly with the decrease in serum total bilirubin levels (P for trend < 0.05). After adjusting for confounding factors, low serum total bilirubin level was shown to be an independent predictor of loss of RKF (hazard ratio [HR] for every 0.1 mg/dL decrease, 1.50; 95% confidence interval [CI], 1.01-2.51; HR [95%CI] for T2 and T1 [vs. T3] 2.03 [0.65-7.88] and 3.70 [1.00-15.9]). This study suggests that low serum total bilirubin levels are associated with the loss of RKF in PD patients.
Identifiants
pubmed: 31207066
doi: 10.1111/1744-9987.12865
doi:
Substances chimiques
Bilirubin
RFM9X3LJ49
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
202-207Informations de copyright
© 2019 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.
Références
Imai E, Horio M, Watanabe T et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 2009;13:621-30.
Collins AJ, Foley RN, Herzog C et al. Renal Data System 2010 Annual Data Report. Am J Kidney Dis 2011;57 (1 Suppl 1):A8, e1-526.
Bargman JM, Thorpe KE, Churchill DN, CPDS G. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001;12:2158-62.
Wang AY, Wang M, Woo J et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 2004;15:2186-94.
Wang AY, Wang M, Woo J et al. A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney Int 2002;62:639-47.
Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Time profiles of peritoneal and renal clearances of different uremic solutes in incident peritoneal dialysis patients. Am J Kidney Dis 2005;46:512-9.
Wang AY, Sea MM, Tang N et al. Resting energy expenditure and subsequent mortality risk in peritoneal dialysis patients. J Am Soc Nephrol 2004;15:3134-43.
Termorshuizen F, Korevaar JC, Dekker FW et al. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of The Netherlands cooperative study on the adequacy of dialysis (NECOSAD )-2. Am J Kidney Dis 2003;41:1293-302.
Nishikawa T, Sasahara T, Kiritoshi S et al. Evaluation of urinary 8-hydroxydeoxy-guanosine as a novel biomarker of macrovascular complications in type 2 diabetes. Diabetes Care 2003;26:1507-12.
Pecoits-Filho R, Heimbürger O, Bárány P et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003;41:1212-8.
Kao MP, Ang DS, Pall A, Struthers AD. Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options. J Hum Hypertens 2010;24:1-8.
Morinaga H, Sugiyama H, Inoue T et al. Effluent free radicals are associated with residual renal function and predict technique failure in peritoneal dialysis patients. Perit Dial Int 2012;32:453-61.
Chung SH, Heimburger O, Stenvinkel P, Qureshi AR, Lindholm B. Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients. Nephrol Dial Transplant 2003;18:590-7.
Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 1987;235:1043-6.
Lanone S, Bloc S, Foresti R et al. Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats. FASEB J 2005;19:1890-2.
Dennery PA, McDonagh AF, Spitz DR, Rodgers PA, Stevenson DK. Hyperbilirubinemia results in reduced oxidative injury in neonatal Gunn rats exposed to hyperoxia. Free Radic Biol Med 1995;19:395-404.
Akboga MK, Canpolat U, Sahinarslan A et al. Association of serum total bilirubin level with severity of coronary atherosclerosis is linked to systemic inflammation. Atherosclerosis 2015;240:110-4.
Li RY, Cao ZG, Zhang JR, Li Y, Wang RT. Decreased serum bilirubin is associated with silent cerebral infarction. Arterioscler Thromb Vasc Biol 2014;34:946-51.
Chan KH, O'Connell RL, Sullivan DR et al. Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate intervention and event lowering in diabetes (FIELD) study. Diabetologia 2013;56:724-36.
Fukui M, Tanaka M, Shiraishi E et al. Relationship between serum bilirubin and albuminuria in patients with type 2 diabetes. Kidney Int 2008;74:1197-201.
Nano J, Muka T, Cepeda M et al. Association of circulating total bilirubin with the metabolic syndrome and type 2 diabetes: a systematic review and meta-analysis of observational evidence. Diabetes Metab 2016;42:389-97.
Han SS, Na KY, Chae D-W, Kim YS, Kim S, Chin HJ. High serum bilirubin is associated with the reduced risk of diabetes mellitus and diabetic nephropathy. Tohoku J Exp Med 2010;221:133-40.
Fujii M, Inoguchi T, Sasaki S et al. Bilirubin and biliverdin protect rodents against diabetic nephropathy by downregulating NAD(P)H oxidase. Kidney Int 2010;78:905-19.
Oh SW, Lee ES, Kim S et al. Bilirubin attenuates the renal tubular injury by inhibition of oxidative stress and apoptosis. BMC Nephrol 2013;14:105.
Tanaka S, Ninomiya T, Masutani K et al. Prognostic impact of serum bilirubin level on long-term renal survival in IgA nephropathy. Clin Exp Nephrol 2015;19:1062-70.
Sakoh T, Nakayama M, Tanaka S et al. Association of serum total bilirubin with renal outcome in Japanese patients with stages 3-5 chronic kidney disease. Metabolism 2015;64:1096-102.
Eriguchi M, Tsuruya K, Yoshida H et al. Extended swan-neck catheter with upper abdominal exit-site reduces peritoneal dialysis-related infections. Ther Apher Dial 2016;20:158-64.
Tsuruya K, Torisu K, Yoshida H et al. Positive association of residual kidney function with hemoglobin level in patients on peritoneal dialysis independent of endogenous erythropoietin concentration. Renal Replacement Therapy 2017;3:47.
Mizuno M, Ito Y, Tanaka A et al. Peritonitis is still an important factor for withdrawal from peritoneal dialysis therapy in the Tokai area of Japan. Clin Exp Nephrol 2011;15:727-37.
Working Group Committee for Preparation of Guidelines for Peritoneal Dialysis JSfDT. Japanese Society for Dialysis T. 2009 Japanese Society for Dialysis Therapy guidelines for peritoneal dialysis. Ther Apher Dial 2010;14:489-504.
Frei B, Stocker R, Ames BN. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci USA 1988;85:9748-52.
Nath KA, d'Uscio LV, Juncos JP et al. An analysis of the DOCA-salt model of hypertension in HO-1−/− mice and the Gunn rat. Am J Physiol Heart Circ Physiol 2007;293:H333-42.